[The problem of an antilipemic synergism between the action of nicotinic acid and the sulphated polyanion SP54 (author's transl)].
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D001798:Blood Proteins / Q000032:analysis; D001799:Blood Sedimentation; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D004357:Drug Synergism; D005260:Female; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood; D014508:Urea / Q000097:blood
D001786:Blood Glucose; D001798:Blood Proteins; D006025:Glycosaminoglycans; D000960:Hypolipidemic Agents; D009539:Nicotinic Acids; D014280:Triglycerides; D014508:Urea; D002784:Cholesterol; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase
Zur Frage eines antilipämischen Wirkungssynergismus zwischen Nicotinsäure und dem sulfatierten Polyanion SP54